Minerva Neurosciences, Inc.
NERV · XNASCIK 1598646fmd_04ZKRR322YSZJ1MQM1BQG5G6WEManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Sep 30, 2026, 55 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 0 | 0 | 0 | 41 | 0 | 0 | 0 | 0 | – |
| Net interest income | – | – | – | – | – | – | – | – | – | – |
| Research and development | 20 | 30 | 35 | 58 | 22 | 32 | 15 | 13 | 12 | 6 |
| Total operating expenses | 30 | 41 | 52 | 76 | 39 | 45 | 25 | 23 | 22 | 15 |
| Operating income | (30) | (41) | (52) | (76) | 2 | (45) | (25) | (23) | (22) | (15) |
| Interest and investment income | 0 | 1 | 2 | 1 | 0 | 0 | 1 | 1 | 1 | 1 |
| Income before taxes | (31) | (41) | (50) | (74) | 2 | (52) | (32) | – | – | – |
| Income tax expense | 0 | (9) | 0 | (2) | – | (2) | – | – | – | – |
| Net income from continuing operations | (31) | (31) | (50) | (72) | – | (50) | – | – | – | – |
| Net income | (31) | (32) | (50) | (72) | 2 | (50) | (32) | (30) | 1 | (293) |
| Net income to common shareholders | – | – | – | – | – | – | – | – | – | – |